Skip to main content

Table 4 Results for all participants recruited during the pollen season

From: Treatment of allergic rhinitis during and outside the pollen season using mobile technology. A MASK study

 

Treatment days

No treatment days

P value*

FF

MPAzeFlu

MF

OAH mono

N users Day 1

331 (5.5%)

159 (2.7%)

351 (5.9%)

1414 (23.6%)

3736 (62.4%)

 

Symptoms Day 1

 Runny nose (%)

69

74

75

78

69

0.77

 Itchy nose (%)

68

55

65

67

57

0.006

 Sneezing (%)

79

73

76

87

77

0.20

 Nasal congestion (%)

75

74

79

71

64

0.37

 Red eyes (%)

50

44

42

52

42

0.56

 Itchy eyes (%)

70

64

68

74

64

0.22

 Watery eyes (%)

48

42

45

54

43

0.29

Impact of symptoms Day 1

 Sleep (%)

44

44

47

41

32

0.70

 Daily activities (%)

41

50

50

49

41

0.36

 Work/school (%)

31

42

33

33

27

0.02

 Bothersome (%)

76

77

77

78

74

0.94

ARIA score (%)

 0

11

11

12

11

16

 

 1

29

26

23

28

32

 

 2

30

24

27

26

24

0.08

 3

19

16

23

21

16

 

 4

12

23

16

15

12

 

 Median [p25-75]

2 [1–3]

2 [1–3]

2 [1–3]

2 [1–3]

2 [1–3]

0.36

VAS global Day 1 (%)

 N

331

159

351

1414

3736

 

 <20

17

18

16

16

30

0.53

 20-49

32

28

33

26

28

 

 ≥50

51

55

51

58

42

 

 Median [p25-75]

50 [28–71]

52 [25–73]

50 [28–68]

55 [30–75]

40 [15–66]

0.72

VAS global – all days (%)

 N days

3186

2594

4093

9780

23,377

 

 N users

507

256

548

2196

4569

 

 Average number of days per user±

6.3

10.1

7.5

4.5

5.1

 

 <20

42

55

52

48

58

0.0001

 20-49

32

27

30

28

24

 

 ≥50

26

18

18

24

18

 

 Median [p25-75]

26 [8–50]

16 [6–38]

19 [7–39]

21 [7–48]

14 [3–38]

0.0001

  1. FF Fluticasone Furoate, MF Mometasone Furoate, MPAzeFlu Azelastine-Fluticasone Propionate
  2. * Comparing MPAzeFlu versus FF or MF. Chi square tests were used for categorical variables (i.e. symptoms and impact of symptoms, ARIA score, global VAS categories); Kruskal–Wallis tests were used for continuous variables (i.e. ARIA score, global VAS)
  3. ±Estimated by dividing the total number of days for which the use of a medication was reported by the total number of users reporting that medication
  4. p25: 25th percentile; p75: 75th percentile